

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma

Information for the public
Published: 4 October 2017

www.nice.org.uk

Brentuximab vedotin (Adcetris) is available on the NHS as a possible treatment for relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

If you are not eligible for treatment, you should be able to continue taking brentuximab vedotin until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[NHS Choices](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Lymphoma Association](#), 0808 808 5555
- [Leukaemia CARE](#), 0808 801 0444
- [Bloodwise](#) (previously Leukaemia & Lymphoma Research), 0808 208 0888
- [Cancer Research UK Patient Information](#) (previously CancerHelp UK), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-1140-0